Zie ook literatuurlijst niet-toxische middelen, voeding en weinig belastende behandelingen specifiek bij borstkanker van arts-bioloog drs. Engelbert Valstar
13 augustus 2021: zie ook dit artikel: https://kanker-actueel.nl/olaparib-een-parpremmer-gegeven-aan-borstkankerpatienten-met-brca-1-en-brca-2-na-operatie-en-chemotherapie-verbetert-ziektevrije-overleving-met-9-procent.html
14 augustus 2020: Bron: The Lancet
Wanneer borstkankerpatiënten met gemuteerde BRCA-1 of BRCA-2 uitgezaaide kanker naast olaparib ook immuuntherapie krijgen met de anti-PD remmer durvalumab als combinatie behandeling dan zijn de eerste resultaten hoopvol. Al is het nog wel prematuur om afgaande op deze studie nu al te zeggen dat dit een toekomstige behandeling kan worden.
Het MEDIOLA-onderzoek is een open-label, fase 1/2, zogeheten basketstudie met durvalumab en olaparib bij solide tumoren verdeeld over meerdere ziekenhuizen.
Tussen 14 juni 2016 en 2 mei 2017 waren 34 patiënten ingeschreven voor deze studie en kregen beide medicijnen toegediend en werden geëvalueerd op veiligheid in eerste instantie.
11 (32%) patiënten kregen bijwerkingen van graad 3 of slechter, waarvan de meest voorkomende bloedarmoede (vier [12%]), neutropenie (drie [9%]) en pancreatitis (twee [6%]) waren.
Drie (9%) patiënten stopten vanwege bijwerkingen en vier (12%) patiënten kregen in totaal zes ernstige bijwerkingen. Er waren geen behandelingsgerelateerde sterfgevallen.
24 (80%; 90% BI 64-390-9) van de 30 patiënten die in aanmerking kwamen voor een effectiviteits analyse hadden na 12 weken de ziekte onder controle. Wat betekent geen ziekte progressie en vermindering van de tumorload.
De studieresultaten: Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study werden gepublicerd in The Lancet. Voor het volledige studieverslag meot betaald worden.
Hier het abstract van deze studie:
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
- et al.
Published:August 06, 2020DOI:https://doi.org/10.1016/S1470-2045(20)30324-7
Summary
Background
Poly (ADP-ribose) polymerase inhibitors combined with immunotherapy have shown antitumour activity in preclinical studies. We aimed to assess the safety and activity of olaparib in combination with the PD-L1-inhibitor, durvalumab, in patients with germline BRCA1-mutated or BRCA2-mutated metastatic breast cancer.
Methods
The MEDIOLA trial is a multicentre, open-label, phase 1/2, basket trial of durvalumab and olaparib in solid tumours. Patients were enrolled into four initial cohorts: germline BRCA-mutated, metastatic breast cancer; germline BRCA-mutated, metastatic ovarian cancer; metastatic gastric cancer; and relapsed small-cell lung cancer. Here, we report on the cohort of patients with breast cancer. Patients who were aged 18 years or older (or aged 19 years or older in South Korea) with germline BRCA1-mutated or BRCA2-mutated or both and histologically confirmed, progressive, HER2-negative, metastatic breast cancer were enrolled from 14 health centres in the UK, the USA, Israel, France, Switzerland, and South Korea. Patients should not have received more than two previous lines of chemotherapy for metastatic breast cancer. Patients received 300 mg olaparib in tablet form orally twice daily for 4 weeks and thereafter a combination of olaparib 300 mg twice daily and durvalumab 1·5 g via intravenous infusion every 4 weeks until disease progression. Primary endpoints were safety and tolerability, and 12-week disease control rate. Safety was analysed in patients who received at least one dose of study treatment, and activity analyses were done in the full-analysis set (patients who received at least one dose of study treatment and were not excluded from the study). Recruitment has completed and the study is ongoing. This trial is registered with ClinicalTrials.gov, NCT02734004.
Findings
Between June 14, 2016, and May 2, 2017, 34 patients were enrolled and received both study drugs and were included in the safety analysis. 11 (32%) patients experienced grade 3 or worse adverse events, of which the most common were anaemia (four [12%]), neutropenia (three [9%]), and pancreatitis (two [6%]). Three (9%) patients discontinued due to adverse events and four (12%) patients experienced a total of six serious adverse events. There were no treatment-related deaths. 24 (80%; 90% CI 64·3–90·9) of 30 patients eligible for activity analysis had disease control at 12 weeks.
Interpretation
Combination of olaparib and durvalumab showed promising antitumour activity and safety similar to that previously observed in olaparib and durvalumab monotherapy studies. Further research in a randomised setting is needed to determine predictors of therapeutic benefit and whether addition of durvalumab improves long-term clinical outcomes compared with olaparib monotherapy.
Funding
AstraZeneca.
References
- 1.
Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family Registry.Cancer Epidemiol Biomarkers Prev. 2009; 18: 1084-1091
- 2.
Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years.Cancer Res. 2006; 66: 8297-8308
- 3.
Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.JAMA. 2017; 317: 2402-2416
- 4.
Two decades beyond BRCA1/2: homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy.Gynecol Oncol. 2015; 137: 343-350
- 5.
Olaparib for metastatic breast cancer in patients with a germline BRCA mutation.N Engl J Med. 2017; 377: 523-533
- 6.
OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.Ann Oncol. 2019; 30: 558-566
- 7.
Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a Phase 1/2 open-label study.JAMA Oncol. 2017; 3e172411
- 8.
NCCN Clinical Practice Guidelines in Oncology: breast cancer. Version 3. 2019.https://www.nccn.org/professionals/physician_gls/pdf/breast.pdfDate: Sept 6, 2019Date accessed: November 29, 2019
- 9.
TECENTRIQ (atezolizumab) prescribing information.https://www.gene.com/download/pdf/tecentriq_prescribing.pdfDate: 2016Date accessed: November 29, 2019
- 10.
IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC).Proc Am Soc Clin Oncol. 2019; 371003
- 11.
Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer.JAMA Oncol. 2019; 5: 1132-1140
- 12.
Safety and clinical activity of the programmed death-ligand 1 inhibitor durvalumab in combination with poly (ADP-ribose) polymerase inhibitor olaparib or vascular endothelial growth factor receptor 1-3 inhibitor cediranib in women's cancers: a dose-escalation, Phase I study.J Clin Oncol. 2017; 35: 2193-2202
- 13.
Beyond DNA repair: the novel immunological potential of PARP inhibitors.Mol Cell Oncol. 2019; 61585170
- 14.
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.Br J Cancer. 2018; 119: 1401-1409
- 15.
PARP inhibition combined with immune checkpoint blockade in SCLC: oasis in an immune desert or mirage?.J Thorac Oncol. 2019; 14: 1323-1326
- 16.
Phase II study of olaparib + durvalumab (MEDIOLA): updated results in the germline BRCA-mutated (BRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC) cohort.Ann Oncol. 2019; 30: v485-v486
- 17.
An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): results in patients with relapsed gastric cancer.Proc Am Soc Clin Oncol. 2019; 37: A140
- 18.
An open-label, multitumor phase II basket study of olaparib and durvalumab (MEDIOLA): results in patients with relapsed SCLC.J Thorac Oncol. 2017; 12: S2044-S2045
- 19.
An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): updated results in patients with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC).Cancer Res. 2018; 79PD5-04
- 20.
Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC).Ann Oncol. 2019; 30: V477
- 21.
An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): results in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC).Cancer Res. 2018; 78PD6-11
- 22.
Analysis of 100 000 human cancer genomes reveals the landscape of tumor mutational burden.Genome Med. 2017; 9: 34
- 23.
A predictive probability design for phase II cancer clinical trials.Clin Trials. 2008; 5: 93-106
- 24.
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.Lancet. 2010; 376: 235-244
- 25.
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.Lancet Oncol. 2018; 19: 497-509
- 26.
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer.N Engl J Med. 2018; 379: 2108-2121
- 27.
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.Ann Oncol. 2015; 26: 259-271
- 28.
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study.Ann Oncol. 2019; 30: 1279-1288
- 29.
Roles of the immune system in cancer: from tumor initiation to metastatic progression.Genes Dev. 2018; 32: 1267-1284
- 30.
Targeting immune checkpoints in breast cancer: an update of early results.ESMO Open. 2017; 2e000255
- 31.
Safety and clinical activity of the programmed death-ligand 1 inhibitor durvalumab in combination with poly (ADP-ribose) polymerase inhibitor olaparib or vascular endothelial growth factor receptor 1-3 inhibitor cediranib in women's cancers: a dose-escalation, phase I study.J Clin Oncol. 2017; 35: 2193-2202
Article Info
Publication History
Published: August 06, 2020
Identification
Copyright
© 2020 Elsevier Ltd. All rights reserved.
ScienceDirect
Access this article on ScienceDirectGerelateerde artikelen
- Olaparib, een parpremmer, gegeven aan borstkankerpatienten met BRCA 1 en BRCA 2 na operatie en chemotherapie verbetert ziektevrije overleving met 9 procent
- Olaparib in combinatie met de PD-L1-remmer, durvalumab, geeft hoopvolle resultaten bij patiënten met erfelijke BRCA1-gemuteerde of BRCA2-gemuteerde uitgezaaide borstkanker.
- Mini stamceltransplantatie (mini-CTC) plus chemo gevolgd door olaparib voor borstkanker stadium III met BRCA-like status komt in basisverzekering
- neratinib plus capecitabine (Xeloda) blijkt alsnog therapeutisch effect te geven bij recidief van HER2-positieve borstkanker met uitzaaiingen in de hersenen
- PARP remmers als monotherapie voor BRCA-1 en BRCA 2 pos. plus HER2-neg. uitgezaaide borstkanker geeft wel langere progressievrije ziekte maar geen verschil in overall overleving in vergelijking met chemotherapie